Auburndale, MA, United States of America

Kevin Delos Parris

This inventor holds 9 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignees: Wyeth, Pfizer Corporation, Millennium Pharmaceuticals Limited. Active years: 2004-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin Delos Parris. Retrieved from https://idiyas.com/inventor/kevin-delos-parris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 2)

% Patents Active = 11.1

CIPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 5.5

ph-index = 4

Forward Citations = 198(Granted Patents)

Location History:

Newton, MA (US) (2005)
Auburndale, MA (US) (2004 - 2012)
Groton, CT (US) (2015 - 2017)

Company Filing History:

Millennium Pharmaceuticals Limited

patents

4. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2017

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9751937 - Antagonist antibodies against GDF-8 and uses therefor (2017-09-05),

2. 8992913 - Antagonist antibodies against GDF-8 and uses therefor (2015-03-31),

3. 8221752 - Antibodies against human interleukin-13 and uses therefor (2012-07-17),

4. 7615213 - Antibodies against human interleukin-13 and pharmaceutical compositions thereof (2009-11-10),

5. 7167802 - Methods for identifying agents that interact with MAP kinase activated protein kinase 2 (2007-01-23),

6. 7135319 - Crystals of an acyl carrier protein synthase/acyl carrier protein complex (2006-11-14),

7. 6957150 - Methods for identifying an agent that interacts with an active site of acyl carrier protein synthase or acyl carrier protein synthase complex (2005-10-18),

8. 6934639 - Methods for designing agents that interact with MMP-13 (2005-08-23),

9. 6684162 - Methods for identifying agents that interact with an active site of acyl carrier protein synthase-acyl carrier protein complex (2004-01-27),

Title: Kevin Delos Parris: Innovator in Antibody Research

Introduction

Kevin Delos Parris is a notable inventor based in Auburndale, MA (US). He has made significant contributions to the field of immunology, particularly through his work on antibodies targeting human interleukin-13. With a total of seven patents to his name, Parris has established himself as a key figure in the development of therapeutic solutions for various IL-13-associated disorders.

Latest Patents

Among his latest patents, Parris has developed antibodies against human interleukin-13 and their pharmaceutical compositions. These applications focus on humanized antibodies and antigen-binding fragments that specifically bind to interleukin-13 (IL-13). The antibodies are designed to regulate immune responses mediated by IL-13, making them useful in diagnosing, preventing, and treating a range of disorders. These include respiratory conditions such as asthma, atopic disorders like allergic rhinitis, and inflammatory or autoimmune conditions affecting the skin and gastrointestinal organs. Additionally, they hold potential in addressing fibrotic and cancerous disorders.

Career Highlights

Throughout his career, Parris has worked with prominent companies, including Wyeth. His experience in the pharmaceutical industry has allowed him to contribute to groundbreaking research and development in antibody therapies. His innovative work has paved the way for advancements in treating complex medical conditions.

Collaborations

Parris has collaborated with notable colleagues, including Laura Lin and Mark L Stahl. These partnerships have further enhanced his research efforts and contributed to the success of his projects.

Conclusion

Kevin Delos Parris is a distinguished inventor whose work in antibody research has the potential to transform the treatment of various IL-13-associated disorders. His innovative patents and collaborations highlight his commitment to advancing medical science.

Profile summary based on public USPTO records.